ABOUT US
Through continuous R&D with the aim of enhancing the health and lives of people,
we will devote ourselves to helping patients live a healthy life
we will devote ourselves to helping patients live a healthy life
-
About REYONWe continue to innovate and pursue the challenge to become a global bio & chemical pharmaceutical company. -
R&DWe are advancing to the global market with our R&D model which building a unique platform founded on production technology and state of the art facility. -
IRA stable and transparent financial structure, the foundation for sustainable growth.
BUSINESS INNOVATIONS
We are creating a future of innovation based on our R&D capabilities and production platform.
Contrast Agents
Generic Medicines
APIs
APIs
Contrast Agents
Generic Medicines
REYON NEWS
We will always dream together with our customers and deliver a message of hope and happiness.
-
.jpg)
REYON Pharmaceutical made a term (MOU) with iNtRON Biotechnology & PHAGERUS for joint development and commercialization of vaccine and treatmentiNtRON Biotechnology(CEO Kyungwon Yoon) and REYON Pharmaceutical (representative directors Sunok Jeong and Yonghwan Yoo) agreed to sign MOU on December 16th for joint development of vaccine platform of fusing PHAGERUS technology and gene therapy specialty for post-corona age. Through this contract, PHAGERUS technology based on bacteriophage which iNtRON Biotechnology holds and REYONs specialty in gene therapy and advanced manufacturing will merge to create a vaccine which specifically target wa...2020.12.16 -
.jpg)
REYON Pharmaceutical entered into an agreement (MOU) on manucfacturing of Corona 19 mRNA vaccine and co-developing later pipeline candidatesREYON Pharmaceutical (representative directors Sunok Jeong and Yonghwan Yoo) signed a MOU with EYEGENE (CEO Wonil Yoo) for joint development of manufacturing COVID-19 Vaccine EG-COVID on November 17th, 2021. (From left, CEO of EYEGENE Wonil Yoo and representative director of REYON Pharmaceutical Yonghwan Yoo) Through the MOU, JinCheon factory will play vital role in mass production of COVID-19 mRNA vaccine named EG-COVID, and transfer the know-how to ChoongJu factory later on. EYEGENE is able t...2020.11.17 -
2020.10.06REYON Pharmaceutical, Super antibiotics Teicoplanin and Arbekacin sulfate are under pre-clinical trial begun for Covid-19In addition to REYON Pharmaceutical (representative directors Sunok Jeong and Yonghwan Yoo) acquiring COVID-19 drug candidate in the late last year, Teicoplanin and Arbekacin sulfate are also added for COVID-19 treatment for pre-clinical trial testing which will start in October 6th. REYON Pharmaceutical is focused on the fact that Teicoplanin, a superbacterial antibiotic, its patent for use was registered in 2016 as a treatment for MERS (Middle East Respiratory Syndrome), and that Corona 19 (C...
-
.jpg)
REYON Pharmaceutical and Neuracle Genetics entered into an agreement regarding AAV gene therapyOn September 16th, representative directors of REYON Pharmaceutical, Sunok Jeong and Yonghwan Yoo, informed that REYON signed a contract regarding AAV gene therapy with Neuracle Genetics (CEO Jongmuk Kim), in which REYON invested 10 billion korean won back in 2018. (From the left, CEO of REYON Pharm Yonghwan Yoo and CEO of Neuracle Genetics Jongmuk Kim) Through this contract, both companies will have the same goal of developing gene therapy of NG101 based on AAV and expect to receive an approva...2020.09.16
8th floor, 416 Yeongdong-daero, Daechi-dong, Gangnam-gu, Seoul, Korea
Copyright©REYON PHARMACEUTICAL CO., LTD. All rights Reserved.